(Total Views: 471)
Posted On: 08/30/2019 7:46:38 PM
Post# of 154880
I found the mono p2 trial publication from last year, it was only available a few days last year for the first 100 downloads before. So for any that had not seen it.
https://www.researchgate.net/profile/Shide_Ba...ection.pdf
Some important items I thought, no changes happened with the rebound group measured at baseline and then after rebound, they just had initially higher ic50 and ic90 values, requiring more Pro 140. Very important showing no resistance was being developed in rebound group, with no anti-PRO 140 antibodies found. Also noting the advantages, weekly dosing, favorable tolerability, limited drug-drug interactions and drug-food interactions (as we say with some other hiv drugs)
Just a reminder, not from the paper, this is why leronlimab is an easy sell vs maraviroc or other current HAART drugs... once it is approved.
https://www.researchgate.net/profile/Shide_Ba...ection.pdf
Some important items I thought, no changes happened with the rebound group measured at baseline and then after rebound, they just had initially higher ic50 and ic90 values, requiring more Pro 140. Very important showing no resistance was being developed in rebound group, with no anti-PRO 140 antibodies found. Also noting the advantages, weekly dosing, favorable tolerability, limited drug-drug interactions and drug-food interactions (as we say with some other hiv drugs)
Just a reminder, not from the paper, this is why leronlimab is an easy sell vs maraviroc or other current HAART drugs... once it is approved.
(3)
(0)
